Table 2.

Five-year relapse-free survival estimates by copy number and patient and tumor characteristics

			5 Year RFS Estimates
	N	Events	Survival	95% CI	P-Value
All	971	252	81.00%	(78.5%, 83.6%)
MET copy number
High	82	29	72.60%	(63.5%, 83.1%)
Normal/Low	889	223	81.80%	(79.3%, 84.5%)	0.0637
PI3KCA copy number
High	134	44	73.10%	(65.7%, 81.3%)
Normal/Low	837	208	82.30%	(79.7%, 85.1%)	0.154
Subtype
HER2-positive	207	62	76.30%	(70.5%, 82.5%)
Hormone receptor-positive	583	137	84.70%	(81.7%, 87.8%)
Triple receptor-negative	173	49	74.20%	(67.8%, 81.3%)	0.071
Age at Diagnosis
<50	371	123	77.40%	(73.2%, 81.9%)
>=50	595	129	83.30%	(80.3%, 86.5%)	0.0003
Tumor size
<2cm	566	116	86.50%	(83.6%, 89.5%)
>=2cm	369	123	73.90%	(69.4%, 78.7%)	<0.0001
Nodal Status
Positive	383	113	86.60%	(83.7%, 89.5%)
Negative	565	130	73.90%	(69.5%, 78.6%)	<0.0001
Grade
1	92	22	85.00%	(77.8%, 92.9%)
2	477	113	83.30%	(79.9%, 86.9%)
3	336	95	77.50%	(73.0%, 82.2%)	0.249
Menopausal Status
Peri/pre-menopausal	312	101	76.30%	(71.5%, 81.3%)
Post-menopausal	624	140	83.90%	(81.0%, 87.0%)	0.0009
Stage
I	304	43	91.90%	(88.8%, 95.1%)
II	662	209	76.00%	(72.7%, 79.5)	<0.0001
Histology
Ductal	898	235	80.70%	(78.0%, 83.4)
Other	58	14	85.30%	(76.3%, 95.2%)	0.826
Chemotherapy
No	480	102	85.20%	(81.9%, 88.6%)
Anthracycline-based	323	110	75.50%	(70.9%, 80.5%)
Anthracycline and Taxane-based	114	24	81.60%	(74.6%, 89.2%)	0.001
Radiation Therapy
Yes	410	109	82.50%	(78.8%, 86.4%)
No	535	134	80.60%	(77.2%, 84.2%)	0.645
Endocrine Therapy
Yes	422	79	87.30%	(84%, 90.6%)
No	522	164	76.80%	(73.1%, 80.6%)	0.0008